Table 1.
Completers (n = 19) | Non-completers (n = 57) | p value | |
---|---|---|---|
Age, years, mean (SD) | 32.5 (7.4) | 32.8 (8.9) | 0.91 |
Male sex, n (%) | 15 (78.9) | 29 (50.9) | 0.034* |
Fulfilment of the modified New York criteria for AS, n (%) | 12 (63.2) | 27 (47.4) | 0.24 |
Symptom duration, years, mean (SD) | 1.1 (1.2) | 1 (1.7) | 0.81 |
HLA-B27 positivity, n (%) | 18 (94.7) | 44 (77.2) | 0.09 |
CRP, mg/l, mean (SD) | 7.5 (10.5) | 12 (15.1) | 0.06 |
Elevated CRP (CRP >5 mg/l), n (%) | 7 (38.9) | 33 (62.3) | 0.09 |
ESR, mm/h, mean (SD) | 16.8 (15.7) | 23.3 (19.5) | 0.21 |
Clinical arthritis, n (%) | 4 (21.1) | 15 (26.3) | 0.65 |
Arthritis joint count, 0–64, mean (SD) | 1.9 (4.4) | 1.8 (4.4) | 0.92 |
Clinical enthesitis, n (%) | 9 (47.4) | 35 (61.4) | 0.40 |
Enthesitis score, 0–17, mean (SD) | 2.8 (2.9) | 4.3 (4.4) | 0.20 |
PGA, 0–10, mean (SD) | 6.1 (1.9) | 7.2 (1.7) | 0.025* |
PhGA, 0–10, mean (SD) | 5.5 (1.5) | 6.5 (1.2) | 0.007* |
ASDAS, units, mean (SD) | 3 (0.7) | 3.5 (0.8) | 0.042* |
BASDAI, 0–10, mean (SD) | 5.4 (1.1) | 5.8 (1.3) | 0.27 |
BASFI, 0–10, mean (SD) | 4 (2.1) | 4.4 (2) | 0.41 |
BASMI linear, 0–10, mean (SD) | 2.4 (0.9) | 2.9 (1.3) | 0.08 |
AS-QoL, 0–18, mean (SD) | 7.6 (3.9) | 10.1 (3.9) | 0.019* |
EQ-5D, 0–1, mean (SD) | 0.7 (0.3) | 0.6 (0.3) | 0.13 |
NSAID intake score, 0–100, mean (SD) | 86.5 (22.1) | 86.1 (47.2) | 0.97 |
Treatment with ETN during 1st year, n (%) | 12 (63.2) | 28 (49.1) | 0.30 |
Significant at p < 0.05.
AS, ankylosing spondylitis; ASQoL, Ankylosing Spondylitis Quality of Life questionnaire; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Disease Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; EQ-5D, Euro Quality of Life Index; ESR, erythrocyte sedimentation rate; HLA, human leukocyte antigen; NSAID, nonsteroidal anti-inflammatory drugs; PhGA, physician’s global assessment; PGA, patient’s global assessment; SD, standard deviation.